{"disease":{"id":"episodic-cluster-headache","name":"episodic cluster headache"},"drugs":{"marketed":[{"drug_id":"galcanezumab","indication_name":"Treatment of episodic cluster headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emgality","generic_name":"GALCANEZUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":60,"revenue":"500","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06882278","title":"Pulsed Radiofrequency Combined With Platelet-Rich Plasma Applied to the Sphenopalatine Ganglion in Treating Episodic Cluster Headache","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":242,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT02945046","title":"A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":169,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT02797951","title":"A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT02397473","title":"A Study Of Galcanezumab In Participants With Episodic Cluster Headache","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Eli Lilly and Company","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}